ArticleThoracic cancer2025
The Burden of Esophageal Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction Until 2036: An Analysis of the Global Burden of Diseases Study 2021.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-term trends in disease burden of esophageal cancer in China and the forecast until 2050.BMC gastroenterology · 2026Article
- The palmitoylation enzyme ZDHHC2 promotes esophageal cancer progression via N-acetylaspartylglutamate.Discover oncology · 2026Article
- Research Progress and Future Directions in Immune Cell Crosstalk in the Esophageal Cancer: A Bibliometric Analysis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn 2022, esophageal cancer (EC) was the eleventh most frequently diagnosed cancer and the seventh leading cause of cancer-related deaths worldwide. Nonetheless, the prevalence and burden of EC in Asian countries have been little studied. This study investigated the prevalence, incidence, and burden of EC in five East Asian countries from 1990 to 2021.
methodsWe retrieved data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 on the prevalence, incidence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) associated with EC in five East Asian countries from 1990 to 2021. The epidemiological characteristics of EC were analyzed by joinpoint regression, age-period-cohort analysis, and decomposition analysis. The burden of EC until 2036 was estimated using autoregressive integrated moving average and Bayesian age-period-cohort models.
resultsAmong these East Asian countries, China had the highest incidence, prevalence, mortality rates, YLLs, YLDs, and DALYs in 1990 and 2021. China and Mongolia exhibited the highest age-standardized incidence rate, age-standardized mortality rate, age-standardized prevalence rate, age-standardized YLDs rate, age-standardized YLLs rate, and age-standardized DALYs rate from 1990 to 2036. The age group with the highest prevalence rate, incidence rate, mortality rate, YLDs rate, YLLs rate, and DALYs rate in these countries was ≥ 55 years. The prevalence and incidence rates in the five countries were influenced by aging and were higher than the global average.
conclusionsThe burden of EC in five East Asian countries was high over the past three decades, particularly among older adults. EC is a significant public health problem in these countries, particularly because of the large population base and aging demographics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.